Literature DB >> 31085684

Bugs as Cancer Drugs: Challenges and Opportunities.

Phillip J Daschner1, Avraham Rasooly2, Jeffrey D White3.   

Abstract

The first nonsurgical cancer therapy was bacterial therapy introduced in 1891 to treat solid tumors. Because in many cases it was harmful and ineffective, and with the emergence of radiotherapy and chemotherapy, bacterial therapy was discontinued. Motivated by the need to improve targeting of solid tumors and in light of recent progress made in developing microbial therapies, the National Cancer Institute has for the first time issued funding opportunities to stimulate research on bacterium-based cancer therapies for conditions under which current cancer therapies are inadequate. This is a work of the U.S. Government and is not subject to copyright protection in the United States. Foreign copyrights may apply.

Entities:  

Keywords:  cancer; microbial; therapy

Mesh:

Substances:

Year:  2019        PMID: 31085684      PMCID: PMC6639246          DOI: 10.1128/MCB.00206-19

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  21 in total

1.  II. Contribution to the Knowledge of Sarcoma.

Authors:  W B Coley
Journal:  Ann Surg       Date:  1891-09       Impact factor: 12.969

2.  Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin.

Authors:  Jin Hai Zheng; Vu H Nguyen; Sheng-Nan Jiang; Seung-Hwan Park; Wenzhi Tan; Seol Hee Hong; Myung Geun Shin; Ik-Joo Chung; Yeongjin Hong; Hee-Seung Bom; Hyon E Choy; Shee Eun Lee; Joon Haeng Rhee; Jung-Joon Min
Journal:  Sci Transl Med       Date:  2017-02-08       Impact factor: 17.956

Review 3.  The mechanism of action of BCG therapy for bladder cancer--a current perspective.

Authors:  Gil Redelman-Sidi; Michael S Glickman; Bernard H Bochner
Journal:  Nat Rev Urol       Date:  2014-02-04       Impact factor: 14.432

4.  Explicit hypoxia targeting with tumor suppression by creating an "obligate" anaerobic Salmonella Typhimurium strain.

Authors:  Bin Yu; Mei Yang; Lei Shi; Yandan Yao; Qinqin Jiang; Xuefei Li; Lei-Han Tang; Bo-Jian Zheng; Kwok-Yung Yuen; David K Smith; Erwei Song; Jian-Dong Huang
Journal:  Sci Rep       Date:  2012-06-01       Impact factor: 4.379

Review 5.  Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy.

Authors:  Laurence M Wood; Yvonne Paterson
Journal:  Front Cell Infect Microbiol       Date:  2014-05-12       Impact factor: 5.293

Review 6.  Bacteria in Cancer Therapy: Renaissance of an Old Concept.

Authors:  Sebastian Felgner; Dino Kocijancic; Michael Frahm; Siegfried Weiss
Journal:  Int J Microbiol       Date:  2016-03-08

Review 7.  Tumour-targeting bacteria-based cancer therapies for increased specificity and improved outcome.

Authors:  Sebastian Felgner; Vinay Pawar; Dino Kocijancic; Marc Erhardt; Siegfried Weiss
Journal:  Microb Biotechnol       Date:  2017-08-03       Impact factor: 5.813

Review 8.  Clinical development of targeted and immune based anti-cancer therapies.

Authors:  N A Seebacher; A E Stacy; G M Porter; A M Merlot
Journal:  J Exp Clin Cancer Res       Date:  2019-04-11

Review 9.  Targeted Cancer Therapy Using Engineered Salmonella typhimurium.

Authors:  Jin Hai Zheng; Jung-Joon Min
Journal:  Chonnam Med J       Date:  2016-09-23

Review 10.  Clostridium novyi-NT in cancer therapy.

Authors:  Verena Staedtke; Nicholas J Roberts; Ren-Yuan Bai; Shibin Zhou
Journal:  Genes Dis       Date:  2016-02-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.